Restoration of INK4a/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias

Oncology Research

Volumn 21, Issue 1, 2013, Pages 23-31

  Bai, Yuansong ^a   Lu, Zhenxia ^a   Lin, Yumei ^a   Sun, Butong ^a   Wang, Shibao ^a   Wang, Guanjun ^b  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Imatinib; INK4a ARF; Lentiviral vector; Philadelphia chromosome (PH) positive leukemia

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; IMATINIB; LENTIVIRUS VECTOR; VIRUS PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; BLAST CELL CRISIS; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; STEM CELL; UMBILICAL CORD BLOOD; VIRAL GENE DELIVERY SYSTEM;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL CYCLE; CELL GROWTH PROCESSES; GENES, P16; HUMANS; LENTIVIRUS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM PROTEINS; PIPERAZINES; PYRIMIDINES; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 84890927773     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13786659070271     Document Type: Article

References (44)

1. Mao, L.; Merlo, A.; Bedi, G.; Shapiro, G. I.; Edwards, C. D.; Rollins, B. J.; Sidransky, D. A novel p16INK4A transcript. Cancer Res. 55:2995-2997; 1995.
2. Quelle, D. E.; Zindy, F.; Ashmun, R. A.; Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000; 1995.
3. Lukas, J.; Parry, D.; Aagaard, L.; Mann, D. J.; Bartkova, J.; Strauss, M.; Peters, G.; Bartek, J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503-506; 1995.
4. Tokarsky-Amiel, R.; Azazmeh, N.; Helman, A.; Stein, Y.; Hassan, A.; Maly, A.; Ben-Porath, I. Dynamics of senescent cell formation and retention revealed by p14ARF induction in the epidermis. Cancer Res.73(9):2829-2839; 2013.
5. Zhang, Y.; Xiong, Y.; Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734;1998.
6. Williams, R. T.; Sherr, C. J. The ARF tumor suppressor in acute leukemias: Insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Adv. Exp. Med. Biol. 604:107-114; 2007.
7. Hirama, T.; Koeffler, H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86:841-854; 1995.
8. Cechova, H.; Lassuthova, P.; Novakova, L.; Belickova, M.; Stemberkova, R.; Jencik, J.; Stankova, M.; Hrabakova, P.; Pegova, K.; Zizkova, H.; Cermak, J. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia. Neoplasma 59:168-174; 2012.
9. Melki, J. R.; Vincent, P. C.; Clark, S. J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 59:3730-3740; 1999.
10. Lewis, J. L.; Chinswangwatanakul, W.; Zheng, B.; Marley, S. B.; Nguyen, D. X.; Cross, N. C.; Banerji, L.; Glassford, J.; Thomas, N. S.; Goldman, J. M.; Lam, E. W.; Gordon, M. Y. The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells. Blood 97:2604-2610; 2001.
11. Rui, H. B.; Su, J. Z . Co-transfection of p16(INK4a) and p53 genes into the K562 cell line inhibits cell proliferation. Haematologica 87:136-142; 2002.
12. Degos, L.; Dombret, H.; Chomienne, C.; Daniel, M. T.; Miclea, J. M.; Chastang, C.; Castaigne, S.; Fenaux, P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643-2653; 1995.
13. Huang, M. E.; Ye, Y. C.; Chen, S. R.; Chai, J. R.; Lu, J. X.; Zhao, L.; Gu, L. J.; Wang, Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572; 1988.
14. Michor, F; Hughes, T. P.; Iwasa, Y.; Branford, S.; Shah, N. P.; Sawyers, C. L.; Nowak, M. A. Dynamics of chronic myeloid leukaemia. Nature 435:1267-1270; 2005.
15. Roumiantsev, S.; Shah, N. P.; Gorre, M. E.; Nicoll, J.; Brasher, B. B.; Sawyers, C. L.; Van Etten, R. A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA 99:10700-10705; 2002.
16. Hochhaus, A.; Kreil, S.; Corbin, A. S.; La Rosee, P.; Muller, M. C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N. C.; Berger, U.; Gschaidmeier, H.; Druker, B. J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196; 2002.
17. Kantarjian, H. M.; Talpaz, M.; O'Brien, S.; Giles, F.; Garcia- Manero, G.; Faderl, S.; Thomas, D.; Shan, J.; Rios, M. B.; Cortes, J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101:473-475; 2003.
18. Castagnetti, F.; Palandri, F.; Amabile, M.; Testoni, N.; Luatti, S.; Soverini, S.; Iacobucci, l.; Breccia, M.; Rege Cambrin, G.; Stagno, F.; Specchia, G.; Galieni, P.; Iuliano, F.; Pane, F.; Saglio, G.; Alimena, G.; Martinelli, G.; Baccarani, M.; Rosti, G. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party. Blood 113:3428-3434; 2009.
19. Cortes, J.; Giles, F.; O'Brien, S.; Thomas, D.; Garcia- Manero, G.; Rios, M. B.; Faderl, S.; Verstovsek, S.; Ferrajoli, A.; Freireich, E. J.; Talpaz, M.; Kantarjian, H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102:83-86; 2003.
20. Mullighan, C. G.; Williams, R. T.; Downing, J. R.; Sherr, C. J. Failure of CDKN2A/B (INK4A/B- ARF) -mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 22:1411-1415; 2008.
21. Bubnoff, von, N.; Schneller, F.; Peschel, C.; Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 359:487-491; 2002.
22. Branford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K. P.; Hughes, T. P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475; 2002.
23. Bai, Y.; Soda, Y.; Izawa, K.; Tanabe, T.; Kang, X.; Tojo, A.; Hoshino, H.; Miyoshi, H.; Asano, S.; Tani, K. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Ther. 10:1446-1457; 2003.
24. Soda; Y.; Tani, K.; Bai, Y.; Saiki, M.; Chen, M.; Izawa, K.; Kobayashi, S.; Takahashi, S.; Uchimaru, K.; Kuwabara, T.; Warashina, M.; Tanabe, T.; Miyoshi, H.; Sugita, K.; Nakazawa, S.; Tojo, A.; Taira, K.; Asano, S. A novel Maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 104:356-363; 2004.
25. Fleckenstein, D. S.; Uphoff, C. C.; Drexler, H. G.; Quentmeier, H. Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk. Res. 26:207-214; 2002.
26. Sen, S.; Takahashi, R.; Rani, S.; Freireich, E. J.; Stass, S. A. Expression of differentially phosphorylated Rb and mutant p53 proteins in myeloid leukemia cell lines. Leuk. Res. 17:639-647; 1993.
27. Amir, S.; Ma, A. H.; Shi, X. B.; Xue, L.; Kung H. J.; Devere White, R. W. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One 8:e61064; 2013.
28. Muer, A.; Overkamp, T.; Gillissen, B.; Richter, A.; Pretzsch, T.; Milojkovic, A.; Dorken, B.; Daniel P.T.; Hemmati, P. p14(ARF)-induced apoptosis in p53 protein-deficient cells is mediated by BH3-only protein-independent derepression of Bak protein through down-regulation of Mcl-1 and Bcl-xL proteins. J. Biol. Chem. 287:17343-17352; 2012.
29. Rocha, S.; Campbell, K. J.; Perkins, N. D. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol. Cell 12:15-25; 2003.
30. Kuo, M. L.; Duncavage, E. J.; Mathew, R.; Besten den, W.; Pei, D.; Naeve, D.; Yamamoto, T.; Cheng, C.; Sherr, C. J.; Roussel, M. F. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res. 63:1046-1053; 2003.
31. Drexler, H.G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845- 859; 1998.
32. Taniguchi, T.; Chikatsu, N.; Takahashi, S.; Fujita, A.; Uchimaru, K.; Asano, S.; Fujita, T.; Motokura, T. Expression of p16INK4A and p14ARF in hematological malignancies. Leukemia 13:1760-1769; 1999.
33. Haidar, M. A.; Cao, X. B.; Manshouri, T.; Chan, L. L.; Glassman, A.; Kantarjian, H. M.; Keating, M. J.; Beran, M. S.; Albitar, M. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood 86:311-315; 1995.
34. Sill, H.; Goldman, J. M.; Cross, N. C. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013-2016; 1995.
35. Serra, A.; Gottardi, E.; Ragione Della, F.; Saglio, G.; Iolascon, A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br. J. Haematol. 91:625-629; 1995.
36. Herman, J. G.; Civin, C. I.; Issa, J. P.; Collector, M. I.; Sharkis, S. J.; Baylin, S. B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 57:837-841; 1997.
37. Iolascon, A.; Della, Ragione, F.; Giordani, L.; Serra, A.; Saglio, G.; Faienza, M. F. Expression of cell cycle regulatory genes in chronic myelogenous leukemia. Haematologica 83:771-777; 1998.
38. Hernandez-Boluda, J. C.; Cervantes, F.; Colomer, D.; Vela, M. C.; Costa, D.; Paz, M. F.; Esteller, M.; Montserrat, E. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: A sequential study in 42 patients. Exp. Hematol. 31:204-210; 2003.
39. Serrano, M.; Lee, H.; Chin, L.; Cordon-Cardo, C.; Beach, D.; DePinho, R. A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37; 1996.
40. van Schanke, A.; van Venrooij, G. M.; Jongsma, M. J.; Banus, H. A.; Mullenders, L. H.; van Kranen, H. J.; de Gruijl, F. R. Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures. Cancer Res. 66:2608-2615; 2006.
41. Gombart, A. F.; Yang, R.; Campbell, M. J.; Berman, J. D.; Koeffler, H. P. Inhibition of growth of human leukemia cell lines by retrovirally expressed wild-type p16INK4A. Leukemia 11:1673-1680; 1997.
42. Quesnel, B.; Preudhomme, C.; Lepelley, P.; Hetuin, D.; Vanrumbeke, M.; Bauters, F.; Velu, T.; Fenaux, P. Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation. Br. J. Haematol. 95:291-298; 1996.
43. Arguello, F.; Alexander, M.; Sterry, J. A.; Tudor, G.; Smith, E. M.; Kalavar, N. T.; Greene, J. F.; Koss, W.; Morgan, C. D.; Stinson, S. F.; Siford, T. J.; Alvord, W. G.; Klabansky, R. L.; Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood 91:2482- 2490; 1998.
44. Park, I. K.; Qian, D.; Kiel, M.; Becker, M. W.; Pihalja, M.; Weissman, I. L.; Morrison, S. J.; Clarke, M. F. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423:302-305; 2003.